Opes Wealth Management Trims Stake in Eli Lilly

Fund reduced holdings in pharmaceutical giant by nearly 73% in Q3

Mar. 19, 2026 at 9:20am

Got story updates? Submit your updates here. ›

Opes Wealth Management LLC, an investment management firm, reduced its stake in Eli Lilly and Company (NYSE: LLY) by 72.9% during the third quarter of 2026, according to a recent SEC filing. The fund now owns 417 shares of the pharmaceutical company's stock, down from 1,536 shares held previously.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, known for developing innovative medicines across a range of therapeutic areas. Institutional investors closely monitor changes in major shareholders' positions, as these can signal shifts in market sentiment or changes to a company's fundamentals.

The details

According to the 13F filing, Opes Wealth Management sold 1,119 shares of Eli Lilly stock during the third quarter, reducing its total position to 417 shares valued at $318,000. The firm cited portfolio rebalancing and risk management as reasons for the stake reduction.

  • Opes Wealth Management filed the 13F report on March 19, 2026, disclosing its Q3 2026 holdings.

The players

Opes Wealth Management LLC

An investment management firm that has reduced its stake in pharmaceutical giant Eli Lilly and Company.

Eli Lilly and Company

A global pharmaceutical company that researches, develops, manufactures, and commercializes a broad range of medicines and therapies for patients worldwide.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Opes Wealth Management's Eli Lilly position, while relatively small, could signal a shift in investor sentiment toward the stock or the broader pharmaceutical industry. However, without further context, it's difficult to draw any firm conclusions about the firm's long-term outlook on Eli Lilly.